Overview of Glp 1 Medications Infographic

Infographic : GLP-1 Medications & The Workforce GLP-1 medications are now among the largest single-class line items on the employer pharmacy ledger, and benefits leaders are being asked to make consequential coverage decisions before the evidence they need fully exists. IBI's new systematic review synthesizes peer-reviewed clinical trials, employer claims studies, health economics analyses, and ...

GLP-1 medications are effective options for weight loss and diabetes. What you need to know is covered in this article and infographic
PDF GLP

Myth: GLP-1 medications remove the need to focus on diet and exercise. Fact: GLP-1 medications can help with weight management, but they don't replace the need for healthy eating and regular ceo exercise. These medications work best when combined with lifestyle changes, like a balanced diet and physical activity, to support long-term health.
The GLP-1 drugs now used for treatment of obesity began as type 2 diabetes drugs. Given the high demand for GLP-1s and rapidly shifting environment with respect to these drugs, learning payers' perspectives is critical.

Useful Notes on Glp 1 Medications Infographic
A GLP-1 Drugs Infographic Download the infographic to see key report statistics about how organizations are viewing GLP-1 coverage for obesity and more.
What are GLP-1 agonists? GLP-1 medications are used to help with weight loss and Type 2 diabetes. They work by acting like a natural hormone in the body called GLP-1 . This hormone helps control blood sugar and hunger. These medications help you feel full for longer, so you eat less and lose weight. They also help lower blood sugar by telling your body to release insulin when needed.

Overview of Glp 1 Medications Infographic
Glucagon-like peptide-1 ( GLP-1 ) receptor agonists are arguably the medication class of the moment. First used to treat type 2 diabetes, then people with overweight or obesity, these agents have ...
This infographic shows key figures on usage/opinion about GLP-1 medication to treat obesity in the U.S.

PDF WHAT ARE GLP
WHAT'S ' NEXT FOR GLP-1 ? Targeting liver diseases (NASH) - Clinical trials are assessing GLP-1 therapies for non-alcoholic steatohepatitis (NASH) and polycystic ovary syndrome (PCOS). More heart-focused variants - Future treatments could see greater cardiovascular benefits or new drugs that are designed specifically for heart health







The Medicare GLP-1 Bridge is a short-term demonstration run by CMS that will provide eligible Medicare Part D beneficiaries with access to certain GLP-1 drugs between July 1 , 2026, and December 31, 2027.